E.G. DOROSH, N.A. KRAVCHUN

V. Danilevsky Institute of Endocrine Pathology Problems of National Academy of Medical sciences of the Ukraine, 10 Artema St., Kharkov, the Ukraine 61002

Dorosh E.G. — graduate student of Department of pharmacotherapy of endocrine diseases, tel. +38057-315-11-88, e-mail: dorosh84@ukr.net¹

Kravchun N.A. — D. med. Sc., Professor, Deputy Director for Science, Head of the Department of pharmacotherapy of endocrine diseases, tel. +38057-315-44-56, e-mail: kravchunna@mail.ru¹

The article studies 8—Iso—prostaglandin level and its relation to metabolic parameters in the patients with type 2 diabetes mellitus (DM) combined with non-alcoholic fatty liver disease (NAFLD). The role of the main indicator of oxidative stress 8-Iso-prostaglandin in NAFLD formation which may be a diagnostic marker of endothelial dysfunction and atherogenesis has been established.

Key words: 8—Iso—prostaglandin, type 2 diabetes mellitus, non-alcoholic fatty liver disease, oxidative stress, lipid peroxidation.

 

 

REFERENCES

1. Ametov A.S. Sakharnyy diabet 2-go tipa. Problemy i resheniya [Type 2 diabetes mellitus. Problems and solutions]. Moscow, GEOTAR-Media Publ., 2012. 704 p.

2. Kozak B.M., Tjota M.Y., Close K.L. International Diabetes Federation (IDF) highlights growing global impact of diabetes in 5th edition of the Diabetes Atlas. Journal of Diabetes, 2012, vol. 4, no. 1, pp. 8-17.

3. Mikhal’chuk L.M., Efіmov A.S. Non-alcoholic fatty liver disease. Mіzhnarodniy endokrinologіchniy zhurnal, 2010, no. 2 (26), pp. 71-82. (in Ukrain.)

4. Khvorostinka V.M., Vlasenko A.V. Effect of fatty liver dystrophy in combination with metabolic syndrome features in course of diabetes. Mіzhnarodniy endokrinologіchniy zhurnal, 2007, no. 5 (11), pp. 65-70. (in Ukrain.)

5. Dedov I.I., Shestakova M.V., eds. Sakharnyy diabet: diagnostika, lechenie, profilaktika [Diabetes mellitus: Diagnosis, treatment, prevention]. Moscow, Medical Information Agency Publ., 2011. 808 p.

6. Day C.P., James O.F.W. Steatohepatitis: A tale of two “hits”? Gastroenterology, 1998, vol. 114, no. 4, pp. 842-845. DOI: 10.1016/S0016-5085(98)70599-2.

7. Garc M.C. Non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology, 2001, vol. 24, pp. 395-402.

8. Fassio E., Alvarez E., Domínguez N., Landeira G., Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology, 2004, vol. 40, no. 4, pp. 820-826. DOI:10.1002/hep.20410.

9. Vendemiale G., Grattagliano I., Caraceni P., Caraccio G., Domenicali M., Dall’Agata M., Trevisani F., et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: Effect of the nutritional status. Hepatology, 2001, vol. 33, no. 4, pp. 808-815. DOI: 10.1053/jhep.2001.23060.

10. Varshavskiy B.Ya., Galaktionova L.P., El’chaninova S.A., Tolmacheva N.V. Activity of intracellular antioxidant enzymes in patients with hypertension. Terapevticheskiy arkhiv, 2000, no. 4, pp. 51-53. (in Russ.).

11. Elesber A.A., Best P.J., Lennon R.J., Mathew V., Rihal C.S., Lerman L.O., Lerman A. Plasma 8-iso-prostaglandin F2alpha, a marker of oxidative stress, is increased in patients with acute myocardial infarction. Free Radical Research, 2006, vol. 40, no. 4, pp. 385-391. DOI: 10.1080/10715760500539154

12. Vladimirov Yu.A. Free radicals in biological systems. Sorosovskiy obrazovatel’nyy zhurnal, 2000, vol. 6, no. 12, pp. 13-19. (in Russ.).

13. Zayika M.N., Kovalyova O.N. 8 isoprostane as a marker of oxidative stress at the patients with chronic heart failure. 16^th European Meeting on Hypertension, Madrid, Spain. 2006. p. 341.

14. Davì G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., Pennese E., Vitacolonna E., Patrono C., et al. In vivo formation of 8-iso-prostaglandin and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation, 1999, vol. 99, no. 2, pp. 224-229.

15. Cracowski J.L., Stanke-Labesque F., Bessard G. Isoprostanes: New markers of oxidative stress. Fundamental and clinical data. Revue de Medecine Interne, 2000, vol. 21, no. 3, pp. 304-307. DOI: 10.1016/S0248-8663(00)80056-9. (in French).

16. Lawson J.A., Rokach J., FitzGerald G.A. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. Journal of Biological Chemistry, 1999, vol. 274, no. 35, pp. 24441-24444. DOI: 10.1074/jbc.274.35.24441.

17. Gerasimchuk N.N., Kovaleva O.N., Safargalina-Kornilova N.A. Level 8-isoprostane, superoxide dismutase and catalase activity in hypertensive patients with overweight and obesity. Kardiovaskulyarnaya terapiya i profilaktika, 2012, no. 11, p. 33. (in Russ.).

18. Greco A., Minghetti L., Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochemical Research, 2000, vol. 25, no. 9-10, pp. 1357-1364.

19. Tacconelli S., Capone M.L., Patrignani P. Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation. Methods in Molecular Biology, 2010, vol. 644, pp. 165-178. DOI: 10.1007/978-1-59745-364-6_14.

20. Duncombe W.G. The colorimetric micro-determination of long-chain fatty acids. Biochemical Journal, 1963, vol. 188, no. 1, pp. 7-10.